TransMedics Group (NASDAQ:TMDX) Price Target Raised to $160.00

TransMedics Group (NASDAQ:TMDX) had its price objective raised by Piper Sandler from $140.00 to $160.00 in a research note released on Wednesday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

A number of other research firms have also commented on TMDX. Canaccord Genuity Group upped their price target on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Needham & Company LLC boosted their target price on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Finally, Morgan Stanley lifted their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $150.67.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $145.26 on Wednesday. The company has a current ratio of 7.14, a quick ratio of 7.13 and a debt-to-equity ratio of 1.06. The company has a 50-day moving average price of $133.80 and a 200-day moving average price of $126.44. The company has a market cap of $4.98 billion, a price-to-earnings ratio of 29.64 and a beta of 2.06. TransMedics Group has a 12 month low of $62.07 and a 12 month high of $156.00.

Insiders Place Their Bets

In related news, Director David Weill sold 5,000 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the transaction, the director directly owned 12,134 shares in the company, valued at $1,682,257.76. This trade represents a 29.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the sale, the chief financial officer directly owned 15,064 shares in the company, valued at $2,103,235.68. The trade was a 5.76% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

Large investors have recently made changes to their positions in the business. Pacer Advisors Inc. purchased a new position in TransMedics Group during the fourth quarter valued at $162,000. Virtu Financial LLC increased its holdings in shares of TransMedics Group by 467.7% during the fourth quarter. Virtu Financial LLC now owns 26,949 shares of the company’s stock valued at $3,278,000 after acquiring an additional 22,202 shares in the last quarter. Corient Private Wealth LLC raised its position in shares of TransMedics Group by 32.5% in the 4th quarter. Corient Private Wealth LLC now owns 3,084 shares of the company’s stock worth $375,000 after purchasing an additional 757 shares during the last quarter. Summit Global Investments raised its position in shares of TransMedics Group by 3.6% in the 4th quarter. Summit Global Investments now owns 3,260 shares of the company’s stock worth $397,000 after purchasing an additional 112 shares during the last quarter. Finally, EP Wealth Advisors LLC bought a new position in TransMedics Group in the 4th quarter worth about $210,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.